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Purpose: To assess the effects of topiramate on C-fiber function, nerve fiber morphology, and 
metabolism (including insulin sensitivity, obesity, and dyslipidemia) in type 2 diabetes.
Patients and methods: We conducted an 18-week, open-label trial treating patients with 
topiramate. Twenty subjects with type 2 diabetes and neuropathy (61.5 ± 1.29 years; 15 male, 
5 female) were enrolled and completed the trial. Neuropathy was evaluated by total neuropathy 
scores, nerve conduction studies, quantitative sensory tests, laser Doppler skin blood flow, and 
intraepidermal nerve fibers in skin biopsies.
Results: Topiramate treatment improved symptoms compatible with C-fiber dysfunction. 
Weight, blood pressure, and hemoglobin A1c also improved. Laser Doppler skin blood flow 
improved significantly after 12 weeks of treatment, but returned to baseline at 18 weeks. After 
18 weeks of treatment there was a significant increase in intraepidermal nerve fiber length at the 
forearm, thigh, and proximal leg. Intraepidermal nerve fiber density was significantly increased 
by topiramate in the proximal leg.
Conclusion: This study is the first to demonstrate that it is possible to induce skin intraepidermal 
nerve fiber regeneration accompanied by enhancement of neurovascular function, translating 
into improved symptoms as well as sensory nerve function. The simultaneous improvement of 
selective metabolic indices may play a role in this effect, but this remains to be determined.
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Introduction
The leading cause of nontraumatic extremity amputation is complications of diabetes, 
with over 96,000 amputations per year.1 Neuropathy associated with diabetes predis-
poses to pain, numbness, ulceration, infection, gangrene, and amputation. Somatic 
and autonomic diabetic neuropathy contribute to 87% of these amputations.2 It is now 
appreciated that there are different forms of neuropathy in diabetes.1 Damage occurs to 
both large, myelinated nerve fibers and small, unmyelinated fibers (C-fibers). The small, 
unmyelinated C-fibers subserve thermal and pain perception, and the small autonomic 
fibers affect sweating and vascular control.3 Damage to small, unmyelinated C-fibers 
has the greatest impact on survival and quality of life, producing initial symptoms 
such as pain, numbness, and anhidrotic skin with disordered skin blood flow (SKBF) 
predisposing to foot ulcers, infection, gangrene and limb loss.4 Diabetic peripheral 
neuropathy is the primary cause of diabetic ulcers and the most predictive diagnosis 
for an eventual amputation. Current therapies for diabetic peripheral neuropathy are 
for symptomatic relief of pain and not for the underlying disorder.5–8 Any addition to 
the therapeutic armamentarium would be welcome.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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It has been shown that small fiber neuropathies are 
  quantifiable with newer tests of C-fiber integrity that 
include quantitative measures of SKBF and corneal confo-
cal microscopy,9–11 quantification of intraepidermal nerve 
fibers (IENF),12–16 and quantitative sensory testing (QST).17 
  Heat-induced vasodilation (44°C), is reduced in subjects with 
impaired glucose tolerance, and in type 2 diabetic patients 
with and without neuropathy.18
We have reported that one of the earliest quantitative 
sensory abnormalities found in people with diabetic periph-
eral neuropathy is the impairment of small fiber sensory 
perception that cosegregates with disordered neurovascular 
function.19,20 Furthermore, there is evidence to suggest that 
one of the early manifestations of C-fiber dysfunction can be 
based upon skin biopsies, with measurement of the density 
of thin, unmyelinated nerve fibers using immunohistochem-
istry for Protein Gene Product 9.5 (PGP-9.5) as a neuronal 
marker.12,13,15,16,21,22 Since description of the utility of PGP-
9.5 as a marker for IENF in human skin,23 it has been used 
for identification of small nerve fibers in the dermis and 
epidermis in a range of small fiber neuropathies, including 
human immunodeficiency virus, and idiopathic small fiber 
and postherpetic neuralgia, among others.13,15,24–29 In addition, 
we have now established that there are characteristic changes 
in IENF that distinguish the metabolic syndrome from diabe-
tes.30 IENF density was recently given a level A recommenda-
tion by the European Federation of the Neurological Societies 
and the Peripheral Nerve Society as a reliable and efficient 
technique to confirm the clinical diagnosis of small fiber 
neuropathy.31 The IENF density has been shown to correlate 
inversely with cold and heat detection thresholds.32 A one-
year diet and exercise intervention program in patients with 
small fiber neuropathy and impaired glucose tolerance led 
to increased IENF density.33 IENF loss is evident early in the 
disease process, declines with increasing neuropathic pain, 
and can be used as an outcome measure in clinical trials.31,33 
Apart from the one-year trial on diet and exercise,33 no drug 
has been shown to induce C-fiber regeneration.
Topiramate, a structurally novel antiepileptic drug, is 
effective in treatment of various types of epilepsy and preven-
tion of migraine headaches. A sulfamate-substituted deriva-
tive of d-fructose, topiramate has several pharmacologic 
properties suggesting it may have potential for overcoming 
the programmed cell death implicated in the pathogen-
esis of neuropathy.4 It enhances gamma aminobutyric acid 
(GABA) activity by interacting with a nonbenzodiazepine 
site on GABA receptors, has negative modulatory effects 
on voltage-activated Na+ channels,34 selectively blocks 
AMPA/kainate glutamate receptors, has negative modulatory 
effects on L-type high voltage-activated Ca2+ channels,35 and 
inhibits the carbonic anhydrase isozymes, CA-I and CA-II.34 
These multiple mechanisms of action may contribute to its 
anticonvulsive, antinociceptive, and putative neuroprotec-
tive properties. There has been no report on the ability of 
topiramate to influence the structure and function of IENF, 
although there are animal studies to suggest that it may 
exercise these properties.36,37
Topiramate thus clearly offers an advantage over agents 
currently used for neuropathy in as much as it relieves pain 
and, in animal studies, is neurotrophic and   neuroprotective, 
and may have beneficial effects on weight, blood pressure, and 
lipids. The American Diabetes Association and the   American 
Society of Pain have recently added topiramate and other 
anticonvulsant medications to the diabetic neuropathy 
  treatment regimen.38 There may be an added benefit with 
topiramate in treating diabetic patients with neuropathy, 
because it exerts both neurotrophic and metabolic effects that 
have not been shown by other anticonvulsants.7,8,39
We have reported on pain reduction with topiramate7 
which persisted for at least six months40 and had salutary 
effects on weight, blood pressure, and serum lipids. The aim 
of this study was to determine whether topiramate induces 
regeneration of small cutaneous nerve fibers in concert with 
improved SKBF and sensory measures of C-fiber function.
Material and methods
Twenty subjects were recruited and completed the study. The 
Eastern Virginia Medical School Institutional Review Board 
approved the study and all subjects gave written informed 
consent prior to any study procedures. All subjects partici-
pating in this study had type 2 diabetes, were aged 35–75 
years, and had documented evidence of diabetic peripheral 
neuropathy. Their baseline demographic and clinical data 
are shown in Table 1. The study was a pure within-subject 
repeated-measure design comparing skin biopsy data, 
sensory responses, and SKBF before and after treatment 
with topiramate in subjects with diabetic peripheral neu-
ropathy. All assessments occurred once prior to treatment 
and again at the end of the 18-week treatment period. In 
addition, SKBF testing was performed at week 12. After 
initial evaluation, all patients received active treatment 
with topiramate.
Quantitative neuropathy testing
All patients had a complete history, and a physical and 
neurologic examination. Neurologic symptom scores and Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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distances, electrode placement, and limb surface temperatures 
were defined for each nerve conduction study to ensure that all 
studies were performed under similar conditions.
Skin blood flow
SKBF was measured by continuous laser Doppler assessment 
of the response to varying stimuli, as previously described.20,43 
Testing was done on the nondominant foot and proximal calf at 
baseline, after six weeks of maintenance treatment (ie, a total of 
12 weeks’ treatment) and at the end of 12 weeks of maintenance 
treatment. The SKBF and temperature probes were placed over 
the external aspect of the nondominant leg 10 cm below the 
knee over the area where the skin biopsy sample was taken 
and on the dorsum of the foot. SKBF examinations were done 
with the patient in a reclined position with the legs elevated 
and completely extended. After a 10-minute baseline period, 
the temperature was increased to 32°C for 10 minutes, 40°C 
for 10 minutes, and then to 44°C for 20 minutes.
Skin biopsy
Skin punch biopsies (3 mm) were performed under local 
anesthesia. Biopsies were collected from each patient’s 
dorsal forearm, lateral thigh (10 cm proximal to patella), 
  lateral proximal leg (10 cm distal to fibular head), and   lateral 
distal leg (10 cm proximal to lateral malleolus). T  issue samples 
were immediately fixed in 2% buffered paraformaldehyde/
lysine/periodate solution for 12–24 hours at 4°C. They were 
subsequently cryoprotected in phosphate buffer with 20% 
glycerol overnight and frozen for later cryosectioning.
Procedures for identifying neurons in skin biopsies 
employed immunofluorescence techniques in a modification 
of the protocol described by McCarthy et al.13 The process-
ing and cutting of the slides were done following procedures 
previously described.30 The skin biopsy data from this 
cohort of patients was also compared with healthy control 
patients taken from the large skin biopsy database created 
and   maintained at our institute.
Fasting blood chemistries
Blood samples were obtained at the screening and final visits 
for determination of glycosylated hemoglobin (HbA1c), lipid 
profile including total serum cholesterol, high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL) 
cholesterol, free fatty acids, and triglycerides, and fasting 
serum glucose and C-peptide. We also measured serum 
B12 and rapid plasma reagin at screening in order to rule 
out occult neuropathies. In addition, liver enzymes were 
measured at screening, and at weeks 4, 6, 12, and 18.
Table 1 Baseline clinical and demographic data (n = 20)
Variable Mean ± SEM
Age (years)  61.5 ± 1.3
race (W:B:A)  16:3:1
gender (male:female)  15:5
height (inches)  70 ± 0.9
Weight (lbs)  228 ± 11.9
BMi (kg/m2)  32.5 ± 1.2 (normal 18.5–24.9)
Waist circumference 
(inches) 
44.5 ± 1.5
Systolic BP (mmhg)  142 ± 4.1 (goal ,130 mmhg in diabetes)
Diastolic BP (mmhg)  81 ± 1.9 (goal ,90 mmhg in diabetes)
Pulse (beats per minute)  81 ± 3.9
Fasting serum glucose 
(mg/dL) 
135 ± 7.6 (normal ,99)
hbA1c (%)  7.4 ± 0.3 (goal ,7 in diabetes)
Total cholesterol mg/dL 175 ± 9.7 (normal ,200)
LDL mg/dL 94 ± 7 (normal ,100)
hDL mg/dL 46 ± 3 (normal male .40, female .50)
Triglyceride mg/dL 176 ± 27 (normal ,150)
Total neuropathy score 
(scored bilaterally) 
31.1 ± 15.5 (normal ,6, severe .40)
cool detection threshold 9 ± 2 (normal 3.0 ± 1.0°c)
Warm detection 
threshold
11 ± 1 (normal 7.8 ± 1.0°c)
Monofilament threshold 5 ± 0.1 (normal 3.9 ± 0.2 log g)
Vibration perception 5.4 ± 2 (normal 0)
Abbreviations: LDL, low-density lipoprotein; hDL, high-density lipoprotein; SeM, 
standard error of mean; hbA1c, glycosylated hemoglobin.
neurologic disability scores were generated by   completion 
of a questionnaire modified from Dyck.41 The sum of the 
three scores (symptom, motor, and sensory scores) is the total 
neuropathy score. Neuropathy was established by the   criteria 
suggested by the American Diabetes   Association and 
  American Academy of Neurology.42 QST included measures 
of temperature and touch perception thresholds. Quantitative 
autonomic function was assessed by three tests, ie, heart rate 
variability during deep breathing at six breaths per minute 
(E:I ratio), the R:R variation in response to the Valsalva 
maneuver, and the R:R variation is response to postural 
change as suggested by the neurologic disability score posi-
tion statement on neuropathy.38
QST was performed using the Medoc device (TSA2001/
VSA3001) following previously published procedures. 
Touch pressure was measured using graded monofilaments 
(Semmes–Weinstein).17 Measurements were taken 2 cm proxi-
mal to the skin biopsy sites on the nondominant limbs.
Nerve conduction studies were performed on the nondomi-
nant peroneal motor, sural sensory, and ulnar motor and sensory 
nerves, using standard techniques of supramaximal percutane-
ous nerve stimulation, surface recording, and appropriate filter-
ing and signal amplification. Stimulation-  to-recording electrode Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Figure 1 A) Mean ± SE dendritic length (Microns) at 4 sites before and after 18 weeks of topiramate treatment. Significant differences (ANOVA) are shown. B) Mean ± Se 
nerve fiber density (Fibers/mm) in skin at different sites before and after 18 weeks of topiramate treatment. A significant change was only found in proximal leg.
Statistical analysis
The primary endpoints were SKBF, QST, and indices of IENF 
density and length, all of which are continuous (parametric) 
data. The independent variable was topiramate treatment. 
Repeated measures analysis of variance was used to exam-
ine the treatment effects for SKBF, QST, and skin biopsies. 
Significant differences were accepted as P , 0.05. Where 
significant treatment differences were observed, contrast 
testing was used to determine the significance at each level, 
while allowing for multiplicity of comparisons. In addition, 
nonparametric Spearman rank correlations were done to 
examine the relationship between IENF, SKBF, and measures 
of neurologic function.
Results
The patients entered into this study were predominantly 
  Caucasian, overweight, male, and hypertensive type 2 diabet-
ics with clinical evidence of distal symmetric polyneuropathy 
(Table 1). Our previous experience prescribing topiramate led 
us to use a low starting dosage and a slow dosage-escalation 
protocol. Oral topiramate was administered initially at a dose 
of 25 mg/day and gradually titrated over six weeks to a dose 
of 100 mg/day or the maximum tolerated dose. Fifteen of the 
20 subjects were able to tolerate 100 mg/day, two subjects 
were maintained on 75 mg/day, and three were on 50 mg/day. 
A 12-week maintenance period followed the titration phase. 
During this period, the dose of study medication remained 
constant. One of the 20 patients was discontinued from 
the study early due to cognitive effects of the medication, 
including psychomotor slowing, word finding difficulty, and 
fatigue. All other patients tolerated their maximally titrated 
dose with little cognitive effect.
We have previously reported16 that mean dendritic length 
and IENF density progressively decreased from proximal 
to distal sites in patients with neuropathy. In this cohort 
of patients, there was a similar decrease in IENF density 
and mean dendritic length from proximal to distal sites 
(Figure 1a and 1b). Nerve fiber density in skin taken from 
patients before topiramate treatment was significantly lower 
than in skin taken from comparable sites in healthy control 
patients in our large skin biopsy database. Comparing the 
results at each site, IENF density in the forearm was signifi-
cantly lower in patients (13.2 ± 3.5) compared with controls 
(32.9 ± 3.2; P , 0.001). Similar deficits in IENF were seen 
in the thigh (8.4 ± 5.7 versus 35.6 ± 7.3; P , 0.01), proximal 
leg (3.1 ± 2.2 versus 17.4 ± 2.0; P , 0.001), and distal leg 
(4.6 ± 4.6 versus 28.0 ± 3.9; P , 0.001).
Mean dendritic length of nerve fibers in skin from controls 
was similar, regardless of site, ie, forearm (3.28 ± 0.18 µm), 
thigh (3.69 ± 0.3 µm), proximal leg (3.34 ± 0.23 µm), and 
distal leg (3.31 ± 0.3 µm). There was a progressive shorten-
ing of fibers in patients before treatment with topiramate 
from forearm to distal leg. In addition, mean dendritic 
length in skin from patients before topiramate treatment was 
significantly lower than skin taken from comparable sites in 
control subjects, ie, thigh (2.28 ± 0.23; P , 0.001), proximal 
leg (1.79 ± 0.26; P , 0.001), and distal leg (1.94 ± 0.35; 
P , 0.005). Mean dendritic length was not different from 
controls in the forearm (2.86 ± 0.19; P . 0.05).
Treatment with topiramate significantly increased mean 
dendritic length in the forearm and proximal leg (Figure 1a) 
and IENF density in the proximal leg (Figure 1b). A represen-
tative sample is shown in Figure 2. This was associated with 
improvement in total neuropathy scores, including touch, 
vibration, and prickling pain thresholds, and reduction in 
weight, body mass index, systolic and diastolic blood pres-
sures, and HbA1c (Table 2). SKBF was measured at baseline, 
12 weeks, and 18 weeks. A significant increase in SKBF was 
seen at week 12, but returned to baseline at week 18. SKBF in 
the leg increased from 87.7 ± 0.1 to 101.3 ± 0.1 (P , 0.001) Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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and in the foot from 102.6 ± 0.2 to 143.7 ± 0.6 (P , 0.001) 
laser Doppler units at 12 weeks. No correlations were found 
between the changes in measures of neurologic function, 
IENF, and the changes in metabolic parameters.
Conclusion
In this small within-subject pilot study, we have shown that 
18 weeks of treatment with topiramate induced improvement 
in neurologic disability scores, including prickling, vibration, 
and touch perception. This was associated with improvement 
in SKBF after 12 weeks of treatment, but this returned to 
baseline at 18 weeks. Quantification of IENF density and 
mean dendritic length in skin biopsies, carried out at entry 
into the study and repeated at the same sites after 18 weeks 
of treatment, showed an increase in nerve fiber length at 
the forearm and proximal leg after treatment with topira-
mate, and an increase in nerve fiber density at the proximal   
leg.
We have previously shown4,44 that the earliest change 
found in patients with the metabolic syndrome without hyper-
glycemia is a reduction in mean dendritic length and that the 
decrease in IENF density occurs after at least five years of 
diabetes and is most prominent at the distal site.44 Thus, the 
patients in this study most closely resemble those with dia-
betes, including those with features of the current   definition 
of the metabolic syndrome (Table 1).
There is a distinct clinical entity of neuropathy associ-
ated with the metabolic syndrome in the absence of glucose 
intolerance. However, up to 50% of patients with painful 
neuropathy may have impaired glucose tolerance.17,45,46 This 
suggests that treatment of the nonhyperglycemic components 
of the metabolic syndrome may be important. While we do 
show an improvement in HbA1c, blood pressure, and weight 
similar to that reported for topiramate in previous neuropathy 
studies,7,39 we could not find correlations between changes 
in nerve fibers or cognitive function and changes in the 
metabolic parameters.
In this study we showed that 18 weeks of treatment 
with topiramate improves total neuropathy scores, touch, 
prickling pain, and vibration perception, as well as IENF. 
We have reported16,44 that distal leg IENF density showed 
significant negative correlations with warm (P , 0.02) and 
cold (P , 0.05) thermal threshold, heat pain (P , 0.05), 
pressure sense (P , 0.05), sensory score (P , 0.03), and 
total neuropathy score (P , 0.03), and thus objective mea-
sures are likely to be related. It is not clear, at this point in 
time, if these changes can be sustained for greater periods. 
It has been shown that pain improvement persists for at 
least six months,40 and anecdotally our patients appeared 
to continue to improve beyond the defined study period. 
Clearly, longer duration studies are needed to determine if 
the cross-sectional correlates of nerve fiber densities and 
mean dendritic length with different sensory modalities can 
be realized.
We have reported that there is a direct correlation 
between distal leg IENF density and duration of diabetes,47 
suggesting that there is a loss of about one nerve fiber per mm 
per year. A reduction of one nerve fiber per mm translates 
into clinically significant changes in total neuropathy scores 
and objective measures of cognitive function. Furthermore, 
an improvement in the proximal leg of three nerve fibers per 
mm was found to provide clinically meaningful changes in 
objective parameters of nerve function. Therefore, we would 
propose that a conservative estimate of double the value 
for change in function, ie, two nerve fibers per mm, could 
be considered a minimal requirement for success in future 
studies of agents affecting nerve biology. Furthermore, we 
have also reported that there is a progressive shortening 
of the mean dendritic length in the distal leg.47 Since this 
Figure 2 A skin biopsy sample before and after treatment with topiramate shows 
an increase in the intraepidermal nerve fiber density (epidermis indicated by box at 
arrow) and dendritic length after treatment.
Table  2  Variables  with  significant  changes  from  baseline  to 
18 weeks post-initiation of treatment with topiramate
Variable Baseline 
(pre)
18 weeks 
(post)
Significance
Weight (lb) 228 ± 11.9 220 ± 12.3 P , 0.0001
BMi 32.5 ± 1.2 31.3 ± 1.3 P , 0.001
Diastolic BP (mmhg)  81 ± 1.9 71 ± 1.6 P , 0.0001
Systolic BP (mmhg)  143 ± 4.1 122 ± 3.1 P , 0.0001
hbA1c (%) 7.4 ± 0.31 6.8 ± 0.20 P , 0.0001
Total neuropathy score
(normal ,6, severe .40)
31.1 ± 15.5 21.0 ± 11.5 P = 0.0026
Touch threshold 2.7 ± 3.1 0.45 ± 1.4 P = 0.004
Prickling threshold  4.3 ± 2.1 2.1 ± 2.4 P = 0.0008
Vibration threshold  5.4 ± 2.3 4.4 ± 2.2 P = 0.039
Abbreviations: BMi, body mass index; BP, blood pressure; hbA1c, hemoglobin A1c.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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change occurs in the metabolic syndrome independent 
of blood glucose,44 it seems that this could be a valuable 
endpoint in patients being treated for components of the 
metabolic syndrome other than hyperglycemia. The pattern 
of regeneration is unique and dictates a need to use IENF 
length, rather than density, as an endpoint in clinical studies 
at sites where viable nerve fibers still exist.
Because of the demonstrated effects of topiramate on 
various metabolic aspects, it could be an important addition 
to therapies aimed at the metabolic syndrome and its seque-
lae, including neuropathy and diabetes. Topiramate has been 
reported to have positive effects on pain relief in diabetic 
peripheral neuropathy,7 an effect which has been shown to 
be durable40 in clinical trials for the management of diabetic 
peripheral neuropathy pain syndromes. In these studies it was 
noted that weight loss and changes in metabolic parameters 
accompanied pain relief, but the role of topiramate in disease 
modification of neuropathy is limited.48 Although the mecha-
nisms underlying the neuroprotective effect of topiramate are 
not fully understood, there may be added benefits for people 
with type 2 diabetes. Topiramate inhibits weight gain in animals 
on a high-fat diet, but the mechanism through which change 
in energy balance is achieved is unclear.49 Topiramate causes 
weight loss50 sustained for one year.51 In our studies, treatment 
with topiramate not only improved symptoms of neuropathy, but 
also reduced body weight, body mass index, systolic and dia-
stolic blood pressure, and HbA1c. These findings are not unlike 
those previously reported with topiramate treatment in normal 
healthy patients, as well as in patients with diabetes.50,51
The caveats, however, are that this was a small open-label 
trial, with careful attention paid to minimizing the untoward 
side effects known to occur at higher doses of topiramate. 
Effects of topiramate on cognitive function, including psy-
chomotor slowing, short-term memory loss, fatigue, and 
anorexia have been reported with topiramate treatment. 
These common side effects make it difficult to design a true 
placebo-controlled trial. In our short study, we found if there 
was a low starting dose (15 mg), and a slow taper to a low 
maximum dose of 100 mg, many of these side effects are 
mitigated. What would be attractive is the discovery of an 
agent with the beneficial neurologic and metabolic effects of 
topiramate, but free of cognitive dysfunction and intensive 
dosing requirements, which would allow a true placebo-
controlled trial to be performed.
Disclosure
The authors report no conflicts of interest in this work. This 
was an inhouse study with no outside funding source.
References
  1.  Vinik A, Pittenger G, McNitt P, Stansberry KB. Diabetic neuropa-
thies: An overview of clinical aspects, pathogenesis, and treatment. 
In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus:   
A Fundamental and Clinical Text. 2nd ed. Philadelphia, PA: Lippincott, 
Williams and Wilkins: 2000.
  2.  Vinik AI,  Suwanwalaikorn  S. Autonomic  neuropathy.  In: 
DeFronzo RA, editor. Current Therapy of Diabetes Mellitus.   
St Louis MO: Mosby; 1997.
  3.  Vinik AI, Erbas T, Park TS. Methods for evaluation of peripheral 
  neurovascular dysfunction. Diabetes Technol Ther. 2001;3:29–50.
  4.  Vinik A, Pittenger G, Anderson A, Stansberry K, McNear E, Barlow P. 
Topiramate improves C-fiber neuropathy and features of the dysmeta-
bolic syndrome in Type 2 diabetes. Diabetes. 2003;52 Suppl 1:A130.
  5.  Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs 
placebo in patients with painful diabetic neuropathy. Pain. 2005;116: 
109–118.
  6.  Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for 
the treatment of painful diabetic peripheral neuropathy: A double-blind, 
placebo-controlled trial. Pain. 2004;110:628–638.
  7.  Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo 
in painful diabetic neuropathy: Analgesic and metabolic effects. 
  Neurology. 2004;63:865–873.
  8.  Ben Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. 
  Predictors of weight loss in adults with topiramate-treated epilepsy. 
Obes Res. 2003;11:556–562.
  9.  Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy 
detects early nerve regeneration after pancreas transplantation in patients 
with type 1 diabetes. Diabetes Care. 2007;30:2608–2612.
  10.  Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation 
of the Norfolk QOL-DN, a new measure of patients’ perception of the 
effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 
2005;7:497–508.
  11.  Stansberry KB. Primary nociceptive afferents mediate the blood flow 
dysfunction in non-glabrous (hairy) skin of type 2 diabetes. Diabetes 
Care. 1999;22:1549–1554.
  12.  Griffin JW, Hsieh ST, McArthur JC, Cornblath DR. Laboratory testing 
in peripheral nerve disease. Neurol Clin. 1996;14:119–133.
  13.  McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in 
sensory neuropathies: Evaluation by skin biopsy. Neurology. 1995;45: 
1848–1855.
  14.  Kennedy WR, Said G. Sensory nerves in skin. Neurology. 1999;53: 
1614–1615.
  15.  Periquet MI, Novak V , Collins MP, et al. Painful sensory   neuropathy: 
Prospective evaluation using skin biopsy. Neurology. 1999;53: 
1641–1647.
  16.  Pittenger  GL,  Ray  M,  Burcus  NI,  McNulty  P,  Basta  B, 
Vinik AI.   Intraepidermal nerve fibers are indicators of small-fiber 
neuropathy in both diabetic and nondiabetic patients. Diabetes Care. 
2004;27:1974–1979.
  17.  Vinik AI, Suwanwalaikorn S, Stansberry KB, Holland MT, McNitt PM, 
Colen LE. Quantitative measurement of cutaneous perception in 
diabetic neuropathy. Muscle Nerve. 1995;18:574–584.
  18.  Krishnan ST, Rayman G. The LDI flare: A novel test of C-fiber func-
tion demonstrates early neuropathy in type 2 diabetes. Diabetes Care. 
2004;27:2930–2935.
  19.  Vinik AI, Erbas T, Park T, Stansberry KB, Pittenger G. Platelet and 
neurovascular dysfunction in diabetes mellitus. Diabetes Care. 2001; 
24:1476–1485.
  20.  Stansberry KB, Hill MA, Shapiro SA, McNitt PM, Bhatt BA, Vinik AI. 
Impairment of peripheral blood flow responses in diabetes resembles 
an enhanced aging effect. Diabetes Care. 1997;20:1711–1716.
  21.  McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal 
nerve fiber density: Normative reference range and diagnostic efficiency. 
Arch Neurol. 1998;55:1513–1520.
  22.  Kennedy W, Said G. Sensory nerves in skin: Answers about painful 
feet? Neurology. 1999;53:1614–1615.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is 
an international, peer-reviewed open-access journal committed to 
the rapid publication of the latest laboratory and clinical findings 
in the fields of diabetes, metabolic syndrome and obesity research.   
Original research, review, case reports, hypothesis formation, expert 
opinion and commentaries are all considered for publication. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
437
Topiramate in type 2 diabetes
  23.  Dalsgaard CJ, Rydh M, Haegerstrand A. Cutaneous innervation in 
man visualized with protein gene product 9.5 (PGP 9.5) antibodies. 
Histochemistry. 1989;92:385–390.
  24.  Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal 
nerve fiber density in HIV-associated sensory neuropathy. Neurology. 
2002;58:115–119.
  25.  Holland NR, Crawford TO, Hauer P. Small-fiber sensory neuropathies: 
Clinical course and neuropathology of idiopathic cases. Ann Neurol. 
1998;44:47–59.
  26.  Petersen KL, Rice FL, Suess F, Berro M, Rowbotham MC. Relief of 
post-herpetic neuralgia by surgical removal of painful skin. Pain. 2002; 
98:119–126.
  27.  Griffin JW, McArthur JC, Polydefkis M. Assessment of cutaneous 
innervation by skin biopsies. Curr Opin Neurol. 2001;14:655–659.
  28.  Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation 
of epidermal nerves in diabetic neuropathy. Neurology. 1996;47: 
1042–1048.
  29.  Chien H, Tseng T, Lin W, et al. Quantitative pathology of cutaneous 
nerve terminal degeneration in the human skin. Acta Neuropathol. 2001; 
102:455–461.
  30.  Pittenger G, Mehrabyan A, Simmons K, et al. Small fiber neuropathy 
is associated with the metabolic syndrome. Metab Syndr Relat Disord. 
2005;3:113–121.
  31.  Lauria G, Lombardi R. Skin biopsy: A new tool for diagnosing periph-
eral neuropathy. BMJ. 2007;334:1159–1162.
  32.  Shun CT, Chang YC, Wu HP, et al. Skin denervation in type 2 diabetes: 
Correlations with diabetic duration and functional impairments. Brain. 
2004;127(Pt 7):1593–1605.
  33.  Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-
diabetic neuropathy. Diabetes Care. 2006;29:1294–1299.
  34.  Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an   inhibitor 
of   carbonic anhydrase isoenzymes. Epilepsia. 2000;41 Suppl 1: 
S35–S39.
  35.  Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of 
  high-voltage-activated calcium channels in dentate granule cells by 
topiramate. Epilepsia. 2001;41 Suppl 1:S52–S60.
  36.  Yang Y, Shuaib A, Muzaffar Q, Siddiqui M. Neuroprotection by delayed 
administration of topiramate in a rat model of middle cerebral artery 
embolization. Brain Res. 1998;804:169–176.
  37.  Lee SR, Kim SP, Kim JE. Protective effect of topiramate against hip-
pocampal neuronal damage after global ischemia in the gerbils. Neurosci 
Lett. 2000;281:183–186.
  38.  Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies:   
A statement by the American Diabetes Association. Diabetes Care. 
2005;28:956–962.
  39.  Thienel U, Neto W, Schwabe SK, Vijapurkar U. Topiramate in painful 
diabetic polyneuropathy: Findings from three double-blind placebo-
controlled trials. Acta Neurol Scand. 2004;110:221–231.
  40.  Donofrio PD, Raskin P, Rosenthal NR, et al. Safety and effectiveness of 
topiramate for the management of painful diabetic peripheral neuropathy 
in an open-label extension study. Clin Ther. 2005;27:1420–1431.
  41.  Dyck PJ. Detection, characterization and staging of polyneuropathy: 
Assessed in diabetes. Muscle Nerve. 1988;11:21–32.
  42.  Consensus Statement. Report and recommendations of the San Antonio 
conference on diabetic neuropathy. American Diabetes Association 
American Academy of Neurology. Diabetes Care. 1988;11:592–597.
  43.  Stansberry KB, Hill M, McNitt PM, Bhatt BA, Vinik AI. Skin blood 
flow reactivity and neuropathy. Diabetes. 1994;43 Suppl 1:107A.
  44.  Pittenger G, Simmons K, Anandacoomaraswamy D, Rice A, Barlow P, 
Vinik A. Topiramate improves intraepidermal nerve fiber morphology 
and quantitative neuropathy measures in diabetic neuropathy patients. 
J Peripher Nerv Syst. 2005;10 Suppl 1;73.
  45.  Sumner C, Sheth S, Griffin J, Cornblath D, Polydefkis M. The spectrum 
of neuropathy in diabetes and impaired glucose tolerance. Neurology. 
2003;60:108–111.
  46.  Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve 
innervation in impaired glucose tolerance and diabetes-associated 
neuropathy. Neurology. 2001;57:1701–1704.
  47.  Pittenger G. Diabetic neuropathy induces N1E-115 neuroblastoma 
cell apoptosis: protective role of topiramate. Grant from RW Johnson 
Pharmaceutical Research Institute; 2004.
  48.  Edwards K, Glantz MJ, Button J. Efficacy and safety of topiramate in 
the treatment of painful diabetic neuropathy: A double-blind, placebo-
controlled study. Neurology. 2000;54 Suppl 3:A81.
  49.  York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body 
weight and body composition of Osborne-Mendel rats fed a high-fat 
diet: Alterations in hormones, neuropeptide, and uncoupling-protein 
mRNAs. Nutrition. 2000;16:967–975.
  50.  Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment 
of obesity. Ann Intern Med. 2005;142:532–546.
  51.  Astrup A, Toubro S. Topiramate: A new potential pharmacological 
treatment for obesity. Obes Res. 2004;12 Suppl:S167–S173.